Cargando…

Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide

Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination,...

Descripción completa

Detalles Bibliográficos
Autores principales: Braga, Antonio, Mora, Paulo, de Melo, Andréia Cristina, Nogueira-Rodrigues, Angélica, Amim-Junior, Joffre, Rezende-Filho, Jorge, Seckl, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390119/
https://www.ncbi.nlm.nih.gov/pubmed/30815369
http://dx.doi.org/10.5306/wjco.v10.i2.28
_version_ 1783398077599580160
author Braga, Antonio
Mora, Paulo
de Melo, Andréia Cristina
Nogueira-Rodrigues, Angélica
Amim-Junior, Joffre
Rezende-Filho, Jorge
Seckl, Michael J
author_facet Braga, Antonio
Mora, Paulo
de Melo, Andréia Cristina
Nogueira-Rodrigues, Angélica
Amim-Junior, Joffre
Rezende-Filho, Jorge
Seckl, Michael J
author_sort Braga, Antonio
collection PubMed
description Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score ≤ 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women.
format Online
Article
Text
id pubmed-6390119
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-63901192019-02-27 Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide Braga, Antonio Mora, Paulo de Melo, Andréia Cristina Nogueira-Rodrigues, Angélica Amim-Junior, Joffre Rezende-Filho, Jorge Seckl, Michael J World J Clin Oncol Editorial Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score ≤ 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women. Baishideng Publishing Group Inc 2019-02-24 2019-02-24 /pmc/articles/PMC6390119/ /pubmed/30815369 http://dx.doi.org/10.5306/wjco.v10.i2.28 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Editorial
Braga, Antonio
Mora, Paulo
de Melo, Andréia Cristina
Nogueira-Rodrigues, Angélica
Amim-Junior, Joffre
Rezende-Filho, Jorge
Seckl, Michael J
Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
title Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
title_full Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
title_fullStr Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
title_full_unstemmed Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
title_short Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
title_sort challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390119/
https://www.ncbi.nlm.nih.gov/pubmed/30815369
http://dx.doi.org/10.5306/wjco.v10.i2.28
work_keys_str_mv AT bragaantonio challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide
AT morapaulo challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide
AT demeloandreiacristina challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide
AT nogueirarodriguesangelica challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide
AT amimjuniorjoffre challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide
AT rezendefilhojorge challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide
AT secklmichaelj challengesinthediagnosisandtreatmentofgestationaltrophoblasticneoplasiaworldwide